Chemical: Drug
dobutamine

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

List of all variant annotations for dobutamine

Gene ? Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
rs1801253 NC_000010.10:g.115805056G>C, NC_000010.11:g.114045297G>C, NG_012187.1:g.6251G>C, NM_000684.2:c.1165G>C, NP_000675.1:p.Gly389Arg, rs12718339, rs17091259, rs28365052, rs59130083
G > C
SNP
G389R
No VIP available CA VA
rs62205366 NC_000020.10:g.57478193T>C, NC_000020.11:g.58903138T>C, NG_016194.1:g.68399T>C, NM_000516.5:c.258-393T>C, NM_001077488.3:c.258-390T>C, NM_001077489.3:c.213-393T>C, NM_001077490.2:c.*119-393T>C, NM_001309840.1:c.81-393T>C, NM_001309861.1:c.81-393T>C, NM_016592.3:c.*161-390T>C, NM_080425.3:c.2187-393T>C, NM_080426.3:c.213-390T>C, NR_003259.1:n.348-393T>C, XM_005260396.1:c.201-393T>C, XM_005260397.1:c.162-393T>C, XM_005260398.1:c.117-393T>C, XM_005260399.1:c.36-393T>C, XM_005260400.1:c.36-393T>C, XM_005260401.1:c.36-393T>C, XM_005260402.1:c.81-390T>C, XR_244140.1:n.1305-390T>C
T > C
SNP
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Generic Names
Trade Names
  • Dobutamina [INN-Spanish]
  • Dobutamine Hcl
  • Dobutamine Hcl in Dextrose 5%
  • Dobutamine Hydrochloride
  • Dobutamine [Usan:Ban:Inn]
  • Dobutamine [Usan]
  • Dobutaminum [INN-Latin]
  • Dobutrex
  • Inotrex
  • Racemic-Dobutamine
Brand Mixture Names

PharmGKB Accession Id

PA449381

Type(s):

Drug

Description

A beta-2 agonist catecholamine that has cardiac stimulant action without evoking vasoconstriction or tachycardia. It is proposed as a cardiotonic after myocardial infarction or open heart surgery.

Source: Drug Bank

Indication

For inotropic support in the short- term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

Dobutamine directly stimulates beta-1 receptors of the heart to increase myocardial contractility and stroke volume, resulting in increased cardiac output.

Source: Drug Bank

Pharmacology

Dobutamine is a direct-acting inotropic agent whose primary activity results from stimulation of the beta-adrenoceptors of the heart while producing comparatively mild chronotropic, hypertensive, arrhythmogenic, and vasodilative effects. Dobutamine acts primarily on beta-1 adrenergic receptors, with little effect on beta-2 or alpha receptors. It does not cause the release of endogenous norepinephrine, as does dopamine. Dobutamine is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Half-Life

2 minutes

Source: Drug Bank

Route of Elimination

In human urine, the major excretion products are the conjugates of dobutamine and 3-O-methyl dobutamine.

Source: Drug Bank

Chemical Properties

Chemical Formula

C18H23NO3

Source: Drug Bank

Isomeric SMILES

CC(CCc1ccc(cc1)O)NCCc2ccc(c(c2)O)O

Source: OpenEye

Canonical SMILES

CC(CCC1=CC=C(O)C=C1)NCCC1=CC(O)=C(O)C=C1

Source: Drug Bank

Average Molecular Weight

301.3801

Source: Drug Bank

Monoisotopic Molecular Weight

301.167793607

Source: Drug Bank

SMILES

CC(CCC1=CC=C(O)C=C1)NCCC1=CC(O)=C(O)C=C1

Source: Drug Bank

InChI String

InChI=1S/C18H23NO3/c1-13(2-3-14-4-7-16(20)8-5-14)19-11-10-15-6-9-17(21)18(22)12-15/h4-9,12-13,19-22H,2-3,10-11H2,1H3

Source: Drug Bank

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Sympathetic Nerve Pathway (Neuroeffector Junction)
    Simplified diagram of a sympathetic neuroeffector junction displaying genes which may be involved.

External Pathways

Links to non-PharmGKB pathways.

PharmGKB contains no links to external pathways for this drug. To report a pathway, click here.

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

EvidenceGene
ADRB1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ADRB2
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
GNAS

Drug Targets

Gene Description
ADRB1 (source: Drug Bank)
ADRB2 (source: Drug Bank)

Drug Interactions

Interaction Description
amitriptyline - dobutamine The tricyclic increases the sympathomimetic effect (source: Drug Bank)
amitriptyline - dobutamine The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect, dobutamine. (source: Drug Bank)
amoxapine - dobutamine The tricyclic increases the sympathomimetic effect (source: Drug Bank)
amoxapine - dobutamine The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of dobutamine. (source: Drug Bank)
clomipramine - dobutamine The tricyclic increases the sympathomimetic effect (source: Drug Bank)
clomipramine - dobutamine The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of dobutamine. (source: Drug Bank)
desipramine - dobutamine The tricyclic increases the sympathomimetic effect (source: Drug Bank)
desipramine - dobutamine The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of dobutamine. (source: Drug Bank)
doxepin - dobutamine The tricyclic increases the sympathomimetic effect (source: Drug Bank)
doxepin - dobutamine The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of dobutamine. (source: Drug Bank)
entacapone - dobutamine Entacapone increases the effect and toxicity of the sympathomimetic, dobutamine. (source: Drug Bank)
guanethidine - dobutamine The agent decreases the effect of guanethidine (source: Drug Bank)
guanethidine - dobutamine Dobutamine may decrease the effect of guanethidine. (source: Drug Bank)
imipramine - dobutamine The tricyclic increases the sympathomimetic effect (source: Drug Bank)
imipramine - dobutamine The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of dobutamine. (source: Drug Bank)
isocarboxazid - dobutamine Increased arterial pressure (source: Drug Bank)
isocarboxazid - dobutamine Increased arterial pressure (source: Drug Bank)
l-methyldopa - dobutamine Increased arterial pressure (source: Drug Bank)
l-methyldopa - dobutamine Increased arterial pressure (source: Drug Bank)
linezolid - dobutamine Possible increase of arterial pressure (source: Drug Bank)
linezolid - dobutamine Possible increase of arterial pressure (source: Drug Bank)
midodrine - dobutamine Increased arterial pressure (source: Drug Bank)
moclobemide - dobutamine Moclobemide increases the sympathomimetic effect (source: Drug Bank)
moclobemide - dobutamine Moclobemide increases the sympathomimetic effect of dobutamine. (source: Drug Bank)
nortriptyline - dobutamine The tricyclic increases the sympathomimetic effect (source: Drug Bank)
nortriptyline - dobutamine The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of dobutamine. (source: Drug Bank)
phenelzine - dobutamine Increased arterial pressure (source: Drug Bank)
phenelzine - dobutamine Increased arterial pressure (source: Drug Bank)
rasagiline - dobutamine Increased arterial pressure (source: Drug Bank)
reserpine - dobutamine Increased arterial pressure (source: Drug Bank)
reserpine - dobutamine Increased arterial pressure (source: Drug Bank)

Relationships from National Drug File - Reference Terminology (NDF-RT)

May Treat
Contraindicated With

Publications related to dobutamine: 4

No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Effects of sex and the common ADRB1 389 genetic polymorphism on the hemodynamic response to dobutamine. Pharmacogenetics and genomics. 2015. Yogev Dotan, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effect of 393T>C polymorphism of GNAS1 gene on dobutamine response in Chinese healthy subjects. Journal of clinical pharmacology. 2009. Mao Yan-Mei, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Beta-adrenergic receptor gene polymorphisms and hemodynamic response to dobutamine during dobutamine stress echocardiography. The pharmacogenomics journal. 2008. Aquilante C L, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The Arg389Gly beta1-adrenoceptor gene polymorphism determines contractile response to catecholamines. Pharmacogenetics. 2004. La Rosée Karl, et al. PubMed

LinkOuts

Web Resource:
Wikipedia
National Drug Code Directory:
55390-560-90
DrugBank:
DB00841
ChEBI:
4670
KEGG Compound:
C06967
KEGG Drug:
D03879
PubChem Compound:
36811
PubChem Substance:
46505241
9181
IUPHAR Ligand:
535
Drugs Product Database (DPD):
2242010
BindingDB:
50028971
ChemSpider:
33786
Therapeutic Targets Database:
DAP000245
FDA Drug Label at DailyMed:
402f24d2-5e67-4dd6-99c6-84bb7c1c29e7

Clinical Trials

These are trials that mention dobutamine and are related to either pharmacogenetics or pharmacogenomics.

No trials found.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, PubChem.